SLC6A2 and neoplasm: Nonetheless, considering that ALK inhibitors have proven effective against high-risk ALK-positive NBL, and given that mIBG is taken up by NBL tumor cells via the norepinephrine transporter (NET) [47], combination therapy with mIBG and brigatinib could potentially lead to improved therapeutic outcomes.